Research map: Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants

Back to the article

Papers in this map

  1. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies · Erik B von Elm · 2007 · 20683 citations · Cited by this paper
  2. Association of front-of-package warning label perceptions with Mediterranean diet adherence after bariatric surgery · 2026 · Related
  3. Health Effects of Overweight and Obesity in 195 Countries over 25 Years · The GBD 2015 Obesity Collaborators · 2017 · 8131 citations · Cited by this paper
  4. Taking back control: The experience of adults using semaglutide and tirzepatide for obesity treatment - A qualitative study · 2025 · Related
  5. Once-Weekly Semaglutide in Adults with Overweight or Obesity · John P.H. Wilding · 2021 · 5054 citations · Cited by this paper
  6. Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series · 2026 · Related
  7. Tirzepatide Once Weekly for the Treatment of Obesity · Ania M. Jastreboff · 2022 · 3661 citations · Cited by this paper
  8. One size does not fit all: Qualitative interviews with individuals with overweight or obesity and healthcare providers on navigating and supporting weight management · 2026 · Related
  9. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension · Giuseppe Mancia · 2023 · 3398 citations · Cited by this paper
  10. Obesity medications and acquired hypothalamic obesity in adults: A two-case experience · 2026 · Related
  11. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes · A. Michael Lincoff · 2023 · 3058 citations · Cited by this paper
  12. The burden of bias: Patient experiences and providers’ perspectives on weight bias · 2026 · Related
  13. Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults · Nowell H Phelps · 2024 · 2417 citations · Cited by this paper
  14. Logistics, effectiveness, safety, and accessibility: Factors determining obesity medication patient preferences from a photovoice analysis · 2025 · Related
  15. Definition and diagnostic criteria of clinical obesity · Francesco Rubino · 2025 · 1676 citations · Cited by this paper
  16. Reporting the effectiveness of dietary intervention on weight loss outcomes in patients with obesity and overweight: a retrospective chart review at a Center of Excellence in UAE · 2025 · Related
  17. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline · Caroline M. Apovian · 2015 · 1348 citations · Cited by this paper
  18. Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation · 2026 · Related
  19. Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force · Sean D. Sullivan · 2013 · 1219 citations · Cited by this paper
  20. Obesity care education in Canadian medical schools: A multi-site qualitative study · 2026 · Related
  21. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021 · Marie Ng · 2025 · 1083 citations · Cited by this paper
  22. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes · Domenica M. Rubino · 2022 · 938 citations · Cited by this paper
  23. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity · Louis J. Aronne · 2025 · 572 citations · Cited by this paper
  24. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity · Eduardo L. Grunvald · 2022 · 342 citations · Cited by this paper
  25. Estimated Sustainable Cost-Based Prices for Diabetes Medicines · Melissa Barber · 2024 · 59 citations · Cited by this paper
  26. Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US · Steven D. Pearson · 2025 · 49 citations · Cited by this paper
  27. Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity · Jennifer H. Hwang · 2025 · 41 citations · Cited by this paper
  28. Using government data to understand the use and availability of medicines for hypertension and diabetes: lessons from Peru · Janeth Tenorio‐Mucha · 2022 · 9 citations · Cited by this paper
  29. OECD Reviews of Health Systems: Peru 2025 · OECD · 2025 · 7 citations · Cited by this paper
  30. Prevalence of diabetes and prediabetes in Peru: a systematic review and meta-analysis · Víctor Juan Vera-Ponce · 2025 · 7 citations · Cited by this paper
  31. Eligibility for obesity management in Peru: Analysis of National Health Surveys from 2014 to 2022 · Antonio Bernabé‐Ortiz · 2024 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)